Increased metabolism in the R6/2 mouse model of Huntington's disease.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neurobiology of Disease

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.NBD.2007.07.029PMID 17920283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Huntington disease

  2010cited by this paper
• Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.

  2007cited by this paper
• Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic Implications

  2007cited by this paper
• The melanocortin system and energy balance.

  2006cited by this paper
• Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.

  2006cited by this paper
• Drug Insight: the functions of ghrelin and its potential as a multitherapeutic hormone

  2006cited by this paper
• The role of CART in body weight homeostasis.

  2006cited by this paper
• Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease

  2006cited by this paper
• Weight changes in Huntington's disease

  2006cited by this paper
• Regional and cellular gene expression changes in human Huntington's disease brain.

  2006cited by this paper
• Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

  2006cited by this paper
• Hypothalamic–endocrine aspects in Huntington's disease

  2006cited by this paper
• Orexin loss in Huntington's disease.

  2005influential reference
• Mitochondria take center stage in aging and neurodegeneration

  2005cited by this paper
• Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice

  2005influential reference
• The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis.

  2005cited by this paper
• Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3.

  2005cited by this paper
• A novel behavioural registration system LABORAS and the social interaction paradigm detect long-term functional deficits following middle cerebral artery occlusion in the rat.

  2005cited by this paper
• The Gut and Energy Balance: Visceral Allies in the Obesity Wars

  2005cited by this paper
• Influence on Spontaneous Tissue Inflammation by the Major Histocompatibility Complex Region in the Nonobese Diabetic Mouse

  2005cited by this paper
• Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing.

  2005cited by this paper
• Normal huntingtin function: an alternative approach to Huntington's disease

  2005cited by this paper
• Reduced ghrelin, islet amyloid polypeptide, and peptide YY expression in the stomach of gastrin-cholecystokinin knockout mice.

  2005cited by this paper
• Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine‐EGFP fluorescent aggregates

  2005cited by this paper
• Overeating of palatable food is associated with blunted leptin and ghrelin responses.

  2005cited by this paper
• CART in feeding and obesity.

  2004cited by this paper
• Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis

  2004cited by this paper
• Brown adipose tissue: function and physiological significance.

  2004cited by this paper
• Decreased UCP2 mRNA Expression in Rat Stomach following Vagotomy: Novel Role for UCP2 as Free Radical Scavenger in the Stomach?

  2004cited by this paper
• Obesity Wars: Molecular Progress Confronts an Expanding Epidemic

  2004cited by this paper
• Peripherally administered [Nle4,D-Phe7]-alpha-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice.

  2004cited by this paper
• Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36).

  2004influential reference
• Neuropeptides in hypothalamic neuronal disorders.

  2004cited by this paper
• Assessment of the nutrition status of patients with Huntington's disease.

  2004cited by this paper
• Obesity wars: molecular progress confronts an expanding epidemic.

  2004cited by this paper
• Brown adipose tissue: function and physiological significance.

  2004cited by this paper
• Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Authors' reply

  2004cited by this paper
• Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice.

  2003cited by this paper
• Evidence for more widespread cerebral pathology in early HD

  2003cited by this paper
• LABORASTM : Initial pharmacological v alidation of a system allowing continuous monitoring of laboratory rodent beha v iour

  2003cited by this paper
• Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma

  2003cited by this paper
• The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease

  2002cited by this paper
• Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

  2002cited by this paper
• Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.

  2002cited by this paper
• Weight loss in early stage of Huntington’s disease

  2002influential reference
• Validation of a new system for the automatic registration of behaviour in mice and rats.

  2001cited by this paper
• Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus.

  2001cited by this paper
• Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation.

  2001cited by this paper
• Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

  2000cited by this paper
• Higher sedentary energy expenditure in patients with Huntington's disease

  2000cited by this paper
• Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene

  2000cited by this paper
• Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation

  1999cited by this paper
• Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation

  1999cited by this paper
• Mice lacking melanin-concentrating hormone are hypophagic and lean

  1998influential reference
• Huntington disease.

  1998cited by this paper
• Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation

  1997cited by this paper
• Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia

  1997cited by this paper
• Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

  1997influential reference
• Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

  1996cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Factors associated with slow progression in Huntington's disease.

  1991cited by this paper
• The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease.

  1991cited by this paper
• Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease

  1990cited by this paper
• Nutritional evaluation of Huntington disease patients.

  1989cited by this paper
• Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease.

  1985influential reference
• Diabetes mellitus in Huntington disease

  1985cited by this paper
• BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS

  1981influential reference
• A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study.

  1962cited by this paper
• Quantitative histology of Wallerian degeneration: I. Nuclear population in rabbit sciatic nerve.

  1946cited by this paper

• Fingolimod Effects on Motor Function and BDNF-TrkB Signaling in a Huntington’s Mouse Model Are Disease-Stage-Dependent

  2026cites this paper
• PROTAC-Mediated Degradation of mHTT Aggregates Attenuates Neurotoxicity in Cellular and R6/2 Mouse Models of Huntington's Disease.

  2026cites this paper
• Development of cognitive, motor, metabolic, and mutant huntingtin aggregation in the zQ175 mouse model of Huntington’s disease

  2025cites this paper
• Metabolic dysregulation in Huntington's disease: Neuronal and glial perspectives.

  2024cites this paper
• Imaging Glucose Metabolism and Dopaminergic Dysfunction in Sheep (Ovis aries) Brain Using Positron Emission Tomography Imaging Reveals Abnormalities in OVT73 Huntington's Disease Sheep.

  2024cites this paper
• Altered Adipocyte Cell Size Distribution Prior to Weight Loss in the R6/2 Model of Huntington’s Disease

  2023cites this paper
• Skeletal muscle regeneration is altered in the R6/2 mouse model of Huntington’s disease

  2022cites this paper
• CryoET reveals organelle phenotypes in huntington disease patient iPSC-derived and mouse primary neurons

  2022cites this paper
• Microarray profiling of hypothalamic gene expression changes in Huntington’s disease mouse models

  2022cites this paper
• The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases.

  2022cites this paper
• Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice

  2022cites this paper
• Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease

  2021cites this paper
• Assessment of In Vivo Muscle Force in the R6/2 Mouse Model of Huntington's Disease Using Newly Designed Force Rig

  2021cites this paper
• The relationship between non-motor features and weight-loss in the premanifest stage of Huntington’s disease

  2021cites this paper
• Hypothalamic pathology in Huntington disease.

  2021cites this paper
• Molecular Mechanisms Underlying Muscle Wasting in Huntington’s Disease

  2020cites this paper
• Rational polytherapy in the treatment of cholinergic seizures.

  2020cites this paper
• Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases.

  2020cites this paper
• Effect of Adenosine Injection Following Cerebral Reperfusion Ischemia on A1AR Gene Expression and Apoptosis in Brain Hippocampal Tissue of Male Wistar Rats

  2020cites this paper
• Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases

  2020cites this paper
• New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington Disease

  2020cites this paper
• Brown Adipose Tissue: A Metabolic Regulator in a Hypothalamic Cross Talk?

  2020cites this paper
• Energy metabolism as a target for new treatment strategies in Huntington’s disease

  2019influential citation
• Metabolic Alterations Amalgamated with Huntington’s Disease

  2019cites this paper
• Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): Compensatory neuroprotection in a neurodegenerative disease?

  2019cites this paper
• The psychopharmacology of Huntington disease.

  2019cites this paper
• Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington's disease.

  2019cites this paper
• The Role of Hypothalamic Pathology for Non-Motor Features of Huntington’s Disease

  2019cites this paper
• Sobre los trastornos nutricionales en las ataxias espinocerebelosas, la enfermedad de Huntington y otras afecciones poliglutamínicas

  2019cites this paper
• Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease.

  2019cites this paper
• Glycation in Huntington’s Disease: A Possible Modifier and Target for Intervention

  2019cites this paper
• Peripheral Expression of Mutant Huntingtin is a Critical Determinant of Weight Loss and Metabolic Disturbances in Huntington’s Disease

  2019cites this paper
• Ghrelin‐mediated improvements in the metabolic phenotype in the R6/2 mouse model of Huntington's disease

  2019cites this paper
• Body composition and bone mineral density in Huntington's disease.

  2019cites this paper
• Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.

  2019cites this paper
• Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington’s Disease

  2018cites this paper
• Large-Brained Animal Models of Huntington's Disease: Sheep.

  2018cites this paper
• Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism

  2018cites this paper
• Body weight is a robust predictor of clinical progression in Huntington disease

  2017cites this paper
• ALLOSTERIC INTERACTIONS WITHIN CANNABINOID RECEPTOR 1 (CB1) AND DOPAMINE RECEPTOR 2 LONG (D2L) HETEROMERS

  2017cites this paper
• Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington’s disease

  2017cites this paper
• Neuroprotective Effect of Matricaria chamomilla Extract on Motor Dysfunction Induced by Transient Global Cerebral Ischemia and Reperfusion in Rat

  2017cites this paper
• Prolonged day length exposure improves circadian deficits and survival in a transgenic mouse model of Huntington's disease

  2016cites this paper
• Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington’s Disease

  2016cites this paper
• Hypothalamic alterations in amyotrophic lateral sclerosis

  2016influential citation
• Brown is the new white: consequences of white adipose tissue alterations in Huntington's disease

  2016influential citation
• A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington’s Disease

  2016cites this paper
• Metabolic disturbances in plasma as biomarkers for Huntington's disease.

  2016cites this paper
• White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington’s Disease

  2016cites this paper
• Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.

  2016cites this paper
• Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.

  2016cites this paper
• Social Behaviour is Impaired in the R6/2 Mouse Model of Huntington's Disease

  2015cites this paper
• Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling

  2015cites this paper
• Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington’s Disease

  2015cites this paper
• Therapeutic strategies for circadian rhythm and sleep disturbances in Huntington disease.

  2015cites this paper
• The power of automated behavioural homecage technologies in characterizing disease progression in laboratory mice: A review

  2015cites this paper
• The clinical utility of multidisciplinary rehabilitation in individuals with Huntington’s Disease

  2015cites this paper
• Obesity and Neurodegeneration: A Focus on Dietary Influence

  2015cites this paper
• Use of Genetically Engineered Mice to Study the Biology of Huntingtin

  2015cites this paper
• Beneficial effects of environmental enrichment and food entrainment in the R6/2 mouse model of Huntington's disease

  2014cites this paper
• Rôle de la dysfonction mitochondriale dans deux maladies neurodégénératives, la Maladie de Huntington et la Maladie de Parkinson

  2014cites this paper
• Energy metabolism and thyroid function of mice with deleted wolframin (Wfs1) gene.

  2014cites this paper
• Impact de l’état et de la prise en charge nutritionnels dans les maladies neurodégénératives : Approche neuroépidémiologique

  2014influential citation
• Hypothalamic Alterations in Huntington's Disease Patients: Comparison with Genetic Rodent Models

  2014cites this paper
• Activation of IGF-1 and Insulin Signaling Pathways Ameliorate Mitochondrial Function and Energy Metabolism in Huntington’s Disease Human Lymphoblasts

  2014cites this paper
• Decreased expression of GLT‐1 in the R6/2 model of Huntington's disease does not worsen disease progression

  2013cites this paper
• A Novel Transgenic Rat Model for Spinocerebellar Ataxia Type 17 Recapitulates Neuropathological Changes and Supplies In Vivo Imaging Biomarkers

  2013cites this paper
• Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.

  2013cites this paper
• Neuropeptide Alterations in the Infundibular Nucleus of Huntington's Disease Patients

  2013cites this paper
• Characteristics, pathophysiology and clinical management of weight loss in Huntington’s disease

  2013cites this paper
• Huntington' disease--imbalance of amino acid levels in plasma of patients and mutation carriers.

  2013cites this paper
• Anorexia and hypothalamic degeneration.

  2013cites this paper
• Voltage-dependent calcium signaling in muscle fibers of mouse models of neuromuscular disorders

  2013cites this paper
• Myeloid cell function in Huntington's disease

  2013cites this paper
• Late onset vascular dysfunction in the R6/1 model of Huntington's disease.

  2013cites this paper
• Automated home cage assessment shows behavioral changes in a transgenic mouse model of spinocerebellar ataxia type 17.

  2013cites this paper
• Early Deficits in Glycolysis Are Specific to Striatal Neurons from a Rat Model of Huntington Disease

  2013cites this paper
• Mouse Models of Mental Illness and Neurological Disease

  2012cites this paper
• Measures of growth in children at risk for Huntington disease

  2012cites this paper
• Operant-based instrumental learning for analysis of genetically modified models of Huntington's disease.

  2012cites this paper
• Huntingtin and mitosis

  2012cites this paper
• An open system for automatic home-cage behavioral analysis and its application to male and female mouse models of Huntington's disease.

  2012cites this paper
• Shaping the role of mitochondria in the pathogenesis of Huntington's disease

  2012cites this paper
• Early Alterations of Brain Cellular Energy Homeostasis in

  2012cites this paper
• Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

  2012cites this paper
• Hypothalamic and Limbic System Changes in Huntington's Disease

  2012cites this paper
• Euglycemic Agent-mediated Hypothalamic Transcriptomic Manipulation in the N171–82Q Model of Huntington Disease Is Related to Their Physiological Efficacy*

  2012cites this paper
• Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases.

  2012cites this paper
• Mouse Models of Polyglutamine Diseases: Review and Data Table. Part I

  2012cites this paper
• Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice.

  2012cites this paper
• Energy deficit in Huntington disease: why it matters.

  2011cites this paper
• No evidence of impaired gastric emptying in early Huntington‘s Disease

  2011cites this paper
• Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies?

  2011cites this paper
• Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

  2011cites this paper
• Molecular Characterization of Skeletal Muscle Atrophy in the R6/2 Mouse Model of Huntington's Disease

  2011cites this paper
• Mutations in cytoplasmic dynein lead to a Huntington's disease-like defect in energy metabolism of brown and white adipose tissues.

  2011cites this paper
• Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice.

  2011cites this paper
• Huntington’s Disease: Quality of Life and Diet

  2011cites this paper
• Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits.

  2011cites this paper
• "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.

  2011cites this paper